Subcutaneous progesterone administration provides a similar ongoing pregnancy rate compared with intramuscular progesterone administration in hormone replacement therapy frozen embryo transfer cycles.

Autor:	Boynukalin FK; Bahceci Health Group, Fulya, Istanbul- Turkey., Abali R; Bahceci Health Group, Fulya, Istanbul- Turkey.; Uskudar University, Department of Obstetrics and Gynecology and Reproductive Medicine, University, Uskudar, Istanbul, Turkey., Gultomruk M; Bahceci Health Group, Fulya, Istanbul- Turkey., Demir B; Bahceci Health Group, Fulya, Istanbul- Turkey., Yarkiner Z; Department of Statistics, Cyprus Science University, Ozankoy, Cyprus., Karlikaya G; Bahceci Health Group, Fulya, Istanbul- Turkey., Bahceci M; Bahceci Health Group, Fulya, Istanbul- Turkey., de Ziegler D; Hospital Foch, Universite de Paris Ouest, Paris, France.
Jazyk:	angličtina
Zdroj:	F&S reports [F S Rep] 2022 Nov 11; Vol. 4 (2), pp. 165-172. Date of Electronic Publication: 2022 Nov 11 (Print Publication: 2023).
DOI:	10.1016/j.xfre.2022.11.002
Abstrakt:	Objective: To compare the ongoing pregnancy rates (OPRs) for subcutaneous progesterone (SC-P) to intramuscular progesterone (IM-P) in hormone replacement therapy used in frozen embryo transfer (FET) cycles. Design: Prospective nonrandomized cohort study. Setting: Private fertility clinic. Patients: The study enrolled 224 patients scheduled for hormone replacement therapy (HRT)-FET cycles with SC-P (n = 133) or IM-P (n = 91). The route of P administration was decided according to the patient's preference and accessibility to the hospital. In the first FET cycle of a freeze-all cycle using single blastocyst transfers, a woman aged ≤35 was included. Main Outcomes: Ongoing pregnancy (OP). Results: The demographic, cycle, and embryologic characteristics were similar between groups. The clinical pregnancy rates (86/133[64.7%] vs. 57/91[62.6%]); miscarriage rates (21/86 [24.4%] vs. 10/57 [17.5%]), and OPR (65/133 [48.9%] vs. 47/91 [51.6%]) were comparable between the SC-P and IM-P groups. Binary logistic regression for OP as the dependent factor revealed that blastocyst morphology was found to be a significant independent prognosticator (for poor quality embryos adjusted odds ratio, 0.11; 95% confidence interval, 0.029-0.427) and progesterone route (SC-P vs. IM-P) was an insignificant prognosticator (adjusted odds ratio, 0.694; 95% confidence interval, 0.354-1.358). Conclusions: The OPR for SC-P administration was similar to that for IM-P in HRT-FET cycles. The effect of ET-day P levels may vary regarding the administration route. Randomized controlled trials comparing different P administration routes are needed, and large-scale prospective trials are warranted to evaluate the ET-day P levels on pregnancy outcome. (© 2022 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu